Bomedemstat

泊美德司他

Report date: 2026/03/27 20:01:50
NME

Base Information

Drug NameBomedemstat
Drug Alias NameIMG-241 bis-tosylate saltBomedemstat ditosylateBomedmestatIMG-7289MK-3543
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysine-specific histone demethylase 1 inhibitors
TargetsLysine-specific histone demethylase 1
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesThrombocythemia, Essential +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImago Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of LincolnCatalent Greenville IncUT Health San Antonio +[8] 
Inactive CompaniesUniversity Of Washington
Active IndicationsPrimary MyelofibrosisThrombocythemia, EssentialHepatic Insufficiency +[5] 
Inactive IndicationsMyelodysplastic SyndromesSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank